-
Article
Open AccessCollaborative artificial intelligence system for investigation of healthcare claims compliance
Healthcare fraud, waste and abuse are costly problems that have huge impact on society. Traditional approaches to identify non-compliant claims rely on auditing strategies requiring trained professionals, or o...
-
Article
Open AccessMinimal genome-wide human CRISPR-Cas9 library
CRISPR guide RNA libraries have been iteratively improved to provide increasingly efficient reagents, although their large size is a barrier for many applications. We design an optimised minimal genome-wide hu...
-
Article
Open AccessFunctional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
Many gene fusions are reported in tumours and for most their role remains unknown. As fusions are used for diagnostic and prognostic purposes, and are targets for treatment, it is crucial to assess their funct...
-
Article
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Functional genomics approaches can overcome limitations—such as the lack of identification of robust targets and poor clinical efficacy—that hamper cancer drug development. Here we performed genome-scale CRISP...
-
Article
Open AccessMicroRNA–mRNA interactions underlying colorectal cancer molecular subtypes
Colorectal cancer (CRC) transcriptional subtypes have been recently identified by gene expression profiling. Here we describe an analytical pipeline, microRNA master regulator analysis (MMRA), developed to sea...
-
Article
Open AccessA diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells
We developed a selectable marker rendering human cells resistant to Diphtheria Toxin (DT). The marker (DTR) consists of a primary microRNA sequence engineered to downregulate the ubiquitous DPH2 gene, a key enzym...
-
Article
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
The development of molecularly targeted anticancer agents relies on large panels of tumour-specific preclinical models closely recapitulating the molecular heterogeneity observed in patients. Here we describe ...
